Metastases of unknown origin. A treatable syndrome

Authors

  • Paula Pimenta Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Francisco Parente Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • J. Diniz Vieira Assistente Graduado de Medicina Interna, Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Borges Alexandrino Chefe de Serviço de Medicina Interna, Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Políbio Serra e Silva Director do Serviços de Medicina II, Serviço de Medicina II dos Hospitais da Universidade de Coimbra

Keywords:

metastasis of unknown origin, chemotherapy, cisplatin

Abstract

Until recently, metastatic disease of unknown origen was always fatal. The recognition that this entity included treatable neoplasms, together with the first reports of highly responsive tumors to combination chemotherapy, lead to more intensive attempts to identify specific clinica[ and pathologic features of this syndrome. The authors present the clinica[ case of a young male with lytic bane metastases, in whom a cisplatin based therapy, resulted in a durable complete remission.

Downloads

Download data is not yet available.

References

Haskell CH, Cochran AJ, Barsky SH, Steckel RJ. Metastasis of unknown origin Current Problems in Cancer 1988; 12(1 ): 1-58.

Greco FA. Hainsworth J0. Cancer of unknown primary site. ln Vicent DeVita Jr. Samuel Hellman, Steven Rosenberg (eds): Cancer Principles & Practice of Oncology. JB Lippincott, Philadelphia, 1993:2072-2093.

Nystrom JS. Van Egmond EM. Leonard RJ. Appropriated theraphy for methastatic cancer of unknown origin. Adv Oncol 1989; 5: 13-19.

Simon AM. Bartucci EJ. The search for the primary tumor in patients with skeletal metastasis of unknown origin. Cancer 1986: 58 1088-1095.

Ultman JE. Phillips TL. Cancer of unknown primary site. ln Vicent DeVita Jr. Samuel Hellman, Steven Rosenberg (eds): Cancer Principles & Practice of Oncology. JB Lippincott. Philadelphia 1989.

Greco FA. Yaughn WK. Hainsworth JD. Advanced poorly differenciated carcinoma of unknown primary site: Recognition ofa treatable syndrome. Ann lntern Med 1986; 104: 547-553.

Hainsworth .10. Greco FA When the primary site is unknow: lssues in diagnosis and management. Adv Oncol 1989; 5: 20-26.

Simon MA. Bartucci EJ. The search for lhe primary tumor in patients with skeletal metastasis of unknown origin. Cancer 1986; 58: 1088-1095.

Mackay B, 0rdonez NG. Tumors of unknown origin: The role of the pathologist. Adv Oncol 1989;5: 13-19.

Bemian CG, Clark RA Diagnostic imaging in cancer. Primary Care 1992; 19(4) 677-712.

Altman E, Cadman E. An analysis of 1539 patients with cancer of unknown primary site. Cancer 1986; 57: 120-124.

Perchalski JE, Hall KL, Dewar MA. Metastasis of unknown origin. Primary Care 1992; 19(4) 747-757.

LeChevalier T, Cvitkovic E, Caille P, Harvey J, Contesso G, Spielmann M., Rouesse J. Early metastatic cancer of unknown primary origin at presentation A clinicai study of 302 consecutive autopsied patients. Arch lntern Med 1988; 148. 2035-2039.

Bradley C, Selby P. ln search of the unknown primary: some may benefit from treatment. BM.I 1992; 304: I 065-1066.

Bitran JD, Ultman JE. Malignancies of undetermined primary origin Disease-a-Month 1992 (April).

Steckel RJ, Kagan AR. Evaluation of the unknown primary neoplasm. Radiol Clin North Am 1982;3: 601-605.

Hainsworth JD, Greco FA. Poorly differentiated carcinoma and gem cell tumors. Hemat/Oncol Clin North Am 1991, 6: 1223-1231

Hainsworth JD. Johnson DH, Greco FA. Poorly differentiated carcinoma of unknown primary site: A newly recognized clinicopathologic entity. Ann lnten Med 1988;109:364-371

McMillan JH, Levine E, Stephens RH. Computed tomography in lhe evaluation of metastatic adenocarcinoma from unknown primary site: a retrospective study. Radiology 1982;143:143-146.

Frost P, Levin B. Clinical implications of metastatic process. Lancet 1992; i: 1458-1461

Seleznick MJ. Tumor markers. Primary Care 1992;4:715-723.

Bartlett NL, Freiha FS. Torti FM. Serum markers in gem cell neoplasms. Hematol/ Oncol Clin North Am 1991;6:1245-1260.

Williams SD. Birch R. Einhom LH et al. Treatment of disseminated gem cell tumors with cisplatin, bleomycin, and either vinblastine and etoposide. New Engl J Med 1987;316:1435-1440.

Bates SE. Clinical applications of serum tumor markers. Ann lntern Med 1991;115623-638.

Einhom LH, Donohue JP. Cis-diamminedichloroplatinium. vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer Ann lntern Med 1977; 87: 293-298

Additional Files

Published

1999-09-30

How to Cite

1.
Pimenta P, Parente F, Vieira JD, Alexandrino B, Serra e Silva P. Metastases of unknown origin. A treatable syndrome. RPMI [Internet]. 1999 Sep. 30 [cited 2024 May 19];6(3):168-73. Available from: https://revista.spmi.pt/index.php/rpmi/article/view/2071

Issue

Vol. 6 No. 3 (1999): Julho/ Setembro

Section

Case Reports

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2023 Medicina Interna

Open Access

Most read articles by the same author(s)

1 2 3 > >>